Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2025-12-26 @ 12:28 AM
Study NCT ID:
NCT06021860
Status:
UNKNOWN
Last Update Posted:
2023-09-28
First Post:
2023-08-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients
Sponsor:
CMP Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-03
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-28
First Submit QC Date:
None
Study First Post Date:
2023-09-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-27
Last Update Post Date:
2023-09-28
Last Update Post Date Type:
ACTUAL